Karyopharm Therapeutics (KPTI) Competitors $3.74 -0.13 (-3.24%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. TVGN, VYGR, ELDN, INBX, BTMD, ACIU, DMAC, SOPH, NGNE, and PLXShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Tevogen Bio (TVGN), Voyager Therapeutics (VYGR), Eledon Pharmaceuticals (ELDN), Inhibrx (INBX), biote (BTMD), AC Immune (ACIU), DiaMedica Therapeutics (DMAC), SOPHiA GENETICS (SOPH), Neurogene (NGNE), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Tevogen Bio Voyager Therapeutics Eledon Pharmaceuticals Inhibrx biote AC Immune DiaMedica Therapeutics SOPHiA GENETICS Neurogene Protalix BioTherapeutics Tevogen Bio (NASDAQ:TVGN) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation. Is TVGN or KPTI more profitable? Tevogen Bio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat Tevogen Bio's return on equity.Company Net Margins Return on Equity Return on Assets Tevogen BioN/A -396.07% 749.97% Karyopharm Therapeutics -52.62%N/A -39.58% Does the media favor TVGN or KPTI? In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 0 mentions for Tevogen Bio. Karyopharm Therapeutics' average media sentiment score of 0.34 beat Tevogen Bio's score of 0.19 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tevogen Bio Neutral Karyopharm Therapeutics Neutral Which has more risk & volatility, TVGN or KPTI? Tevogen Bio has a beta of -1.07, indicating that its stock price is 207% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Which has stronger valuation & earnings, TVGN or KPTI? Tevogen Bio has higher earnings, but lower revenue than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTevogen BioN/AN/A-$70KN/AN/AKaryopharm Therapeutics$145.24M0.22-$143.10M-$15.29-0.25 Do analysts rate TVGN or KPTI? Tevogen Bio presently has a consensus price target of $7.10, indicating a potential upside of 610.00%. Karyopharm Therapeutics has a consensus price target of $57.50, indicating a potential upside of 1,389.64%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Tevogen Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in TVGN or KPTI? Karyopharm Therapeutics received 538 more outperform votes than Tevogen Bio when rated by MarketBeat users. However, 100.00% of users gave Tevogen Bio an outperform vote while only 72.42% of users gave Karyopharm Therapeutics an outperform vote. CompanyUnderperformOutperformTevogen BioOutperform Votes3100.00% Underperform VotesNo VotesKaryopharm TherapeuticsOutperform Votes54172.42% Underperform Votes20627.58% Do institutionals & insiders believe in TVGN or KPTI? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 56.6% of Tevogen Bio shares are owned by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryKaryopharm Therapeutics beats Tevogen Bio on 9 of the 14 factors compared between the two stocks. Remove Ads Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.49M$6.73B$5.54B$7.49BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-3.786.9923.2518.07Price / Sales0.22198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book-2.635.926.493.99Net Income-$143.10M$142.37M$3.21B$247.18M7 Day Performance-11.26%-9.32%-6.42%-6.42%1 Month Performance-46.76%-10.26%-0.68%-7.44%1 Year Performance-79.97%-15.08%6.05%-4.31% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.3284 of 5 stars$3.74-3.2%$57.50+1,439.5%-80.0%$31.44M$145.24M-3.66380Gap DownTVGNTevogen Bio3.317 of 5 stars$1.24+8.3%$7.10+474.9%-61.8%$216.19MN/A0.003VYGRVoyager Therapeutics4.445 of 5 stars$3.91+0.7%$14.86+280.1%-66.7%$215.80M$80.00M5.51100Gap DownELDNEledon Pharmaceuticals1.5133 of 5 stars$3.61+2.7%$12.50+246.7%+87.0%$215.36MN/A-1.7910Gap UpINBXInhibrx1.8898 of 5 stars$14.74+2.7%N/A-62.0%$213.30M$200,000.000.00166News CoveragePositive NewsBTMDbiote3.4508 of 5 stars$3.91+1.4%$8.00+104.4%-43.1%$212.62M$197.19M15.05194Insider TradePositive NewsGap UpACIUAC Immune2.5154 of 5 stars$2.11+0.5%$12.00+468.7%-36.8%$211.87M$27.31M-4.59140Analyst ForecastShort Interest ↑News CoverageDMACDiaMedica Therapeutics1.1235 of 5 stars$4.94-0.8%$8.00+61.9%+31.4%$211.71MN/A-8.8220SOPHSOPHiA GENETICS2.8536 of 5 stars$3.14+3.8%$6.80+116.9%-41.7%$209.06M$65.17M-2.88520Gap UpNGNENeurogene2.421 of 5 stars$13.94-1.9%$60.80+336.1%-78.0%$207.11M$925,000.000.0090Gap DownPLXProtalix BioTherapeutics1.9617 of 5 stars$2.60+4.2%$15.00+478.0%+109.7%$202.50M$53.40M-19.96200Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Tevogen Bio Competitors Voyager Therapeutics Competitors Eledon Pharmaceuticals Competitors Inhibrx Competitors biote Competitors AC Immune Competitors DiaMedica Therapeutics Competitors SOPHiA GENETICS Competitors Neurogene Competitors Protalix BioTherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KPTI Stock Free KPTI Stock Alerts